Recent studies have demonstrated that Cbl, the 120 kDa protein product of the c-cbl proto-oncogene, becomes tyrosine phosphorylated in response to stimulation of growth factor receptors and upon integrin-mediated cell adhesion. As a result, Cbl forms complexes with SH2 and SH3 domain-containing proteins, pointing to its role in signal transduction. The cellular form of Cbl can be rendered into transforming by naturally occurring or engineered mutations to its amino acid sequence. To gain insight into the mechanisms how oncogenic forms of Cbl render cells tumorigenic and what the function of the cellular Cbl might be, we have undertaken an analysis of NIH3T3 cells transfected with wild-type and oncogenic forms of Cbl. We demonstrate that unlike cellular Cbl, the mutant forms of Cbl are tyrosine phosphorylated in an adhesion-independent manner and interact with and activate SH2-containing signaling molecules in both suspended and adherent cells. Our data further show that oncogenic forms of Cbl induce anchorage-independent but serum-dependent growth. These results support the view that transformation by oncogenic forms of Cbl results from constitutive activation of integrin-dependent, rather than growth factor-dependent signaling events and, as a corollary, suggest that cellular Cbl might be a functionally important mediator of integrin signaling.
Introduction
Both cell attachment to extracellular matrix (ECM) and mitogenic stimulation by growth factors are necessary for survival and proliferation of most types of normal cells (Tucker et al., 1981; Frisch and Ruoslahti, 1997) . In contrast, malignant cells are generally able to grow in the absence of growth factors or contacts with ECM. Adhesion-and growth factor requirement for proliferation may therefore function as a safeguard for the organism as apoptosis of cells in inappropriate environments would prevent invasion and metastasis. As a corollary, inadvertent activation of intracellular signaling components downstream of integrins and growth factor receptors may lead to malignant transformation. Indeed, recent studies have revealed that a number of proteins involved in mitogenic growth factor signaling are encoded by genes originally identi®ed as protooncogenes, such as the small GTP-binding protein Ras and the pathway downstream of it (for a review, see Marte and Downward, 1997) . In contrast, relatively little is known about the oncogenic potential of the components in the integrin signaling pathway. Recently, Frisch et al. found that expression of an activated form of FAK, a novel tyrosine kinase found to be a component of integrin signaling (for a review, see Hanks and Polte, 1997) , induces anchorageindependent, but serum-dependent growth of epithelial cells. Consequently, cells expressing the activated form of FAK were tumorigenic in nude mice (Frisch et al., 1996) . Observations made by Schwartz et al. (1996) in turn demonstrate that lbc and dbl, which are guanine nucleotide exchange factors for Rho, activate an integrin-dependent, but not growth factor-dependent pathway, and make cells anchorage-independent and tumorigenic. Together, these ®ndings suggest that constitutive activation of the integrin signaling pathway alone, without concomitant activation of the growth factor pathway, may be sucient for cell transformation.
The proto-oncogene p120 cbl (Cbl) was originally identi®ed as the cellular homologue of the transforming protein of the Cas NS-1 retrovirus that induces pre-B cell lymphomas and myeloid tumors in mice (Langdon et al., 1989) . The cellular form of Cbl can be rendered transforming by mutations: a mutant form of Cbl with a 17 amino acid deletion (Figure 1 ), which was cloned from a pre-B lymphoma cell line (70Z/3), is oncogenic when transfected into NIH3T3 cells (Blake and Langdon, 1992; Andoniou et al., 1994) . Additionally, mutant proteins with small deletions within this 17 amino acid stretch also induced transformation of NIH3T3 cells (Andoniou et al., 1994) . Although the oncogenicity of mutant forms of Cbl is well documented, the function of wild-type Cbl, which is nontransforming even when overexpressed (Andoniou et al., 1994) , has remained unclear. Cbl, which is mainly expressed in hematopoietic cells, lacks any obvious catalytic domains. Instead, Cbl possesses multiple potential tyrosine phosphorylation sites and proline-rich motifs, which could mediate concurrent association with SH2-and SH3-domain-containing polypeptides, respectively. Cbl also has a carboxyterminal leucine zipper, a motif known to promote homo-and heterodimerization of other proteins, a RING ®nger structure thought to mediate proteinprotein or protein-DNA interactions, and a recently identi®ed phosphotyrosine-binding (PTB) domain (Thien and ; for a review, see Langdon, 1995) . Thus, Cbl is well-suited for a potential role in assembling intracellular signaling complexes. In support of this, tyrosine phosphorylation of Cbl and binding to SH2-containing molecules has been reported to occur in response to a number of stimuli, including activation of tyrosine kinase receptors for epidermal growth factor (EGF), plateletderived growth factor (PDGF) and ®broblast growth factor (FGF) (Bowtell and Langdon, 1995; Fukazawa et al., 1996; Galisteo et al., 1995; Meisner and Czech, 1995; Tanaka et al., 1995) . We reported recently that Cbl becomes phosphorylated upon integrin-mediated cell adhesion, and forms complexes with a number of SH2-domain-containing signaling molecules, such as Src and phosphatidylinositol 3'-kinase (PI 3-kinase) (Ojaniemi et al., 1997) . These results indicate that Cbl is a point of convergence in the actions of a variety of factors, and may be a downstream component in both growth factor and integrin signaling pathways.
To gain insight into the mechanisms of how oncogenic forms of Cbl can render cells tumorigenic and what the function of the cellular Cbl might be, we have undertaken an analysis of NIH3T3 cells transfected with wild-type and oncogenic forms of Cbl. Our results demonstrate that expression of oncogenic forms of Cbl, but not wild-type c-Cbl, induces deregulation of the endogenous tyrosine phosphorylation machinery so that requirement for integrin-mediated cell adhesion in some intracellular signaling events is bypassed in these cells. Our data further show that oncogenic forms of Cbl induce anchorage-independent but serum-dependent growth. These results support the view that transformation by oncogenic forms of Cbl results from constitutive activation of integrin-dependent signaling events and suggest that cellular Cbl might be a functionally important mediator of integrin signaling.
Results
Oncogenic Cbl mutants are tyrosine phosphorylated in an adhesion-independent manner and interact with SH2-proteins in both suspended and adherent cells
We have previously demonstrated that the endogenous, cellular form of Cbl, c-Cbl, is tyrosine phosphorylated in an adhesion-dependent manner (Ojaniemi et al., 1997) . To investigate whether tyrosine phosphorylation of the oncogenic forms of Cbl is regulated in an integrin ligand binding-dependent manner, we utilized previously established NIH3T3 ®broblast transfectants expressing either wild-type human Cbl (c-Cbl), or three mutant forms of Cbl: Y368del, in which the tyrosine 368 is deleted, Y371del, in which the tyrosine 371 is deleted and 70Z/Cbl, which contains a 17 amino acid deletion of amino acids 366 ± 382 (see Figure 1 and Andoniou et al., 1994) . It has been demonstrated earlier that the mutant Cbl transfectants are tumorigenic in nude mice, and as observed previously, we found that NIH3T3 transfectants expressing mutant Cbl proteins exhibited a transformed phenotype in culture whereas the wild-type Cbl-expressing cells remained untransformed (data not shown and Andoniou et al., 1994) .
In order to assess the overall tyrosine phosphorylation status of intracellular proteins in the various transfectants, total cell lysates prepared from cells either kept in suspension or plated on dishes coated with ®bronectin were analysed by anti-phosphotyrosine blotting. Parental NIH3T3 cells and the various transfectants adhere to ®bronectin in an a5b1 integrin-dependent manner, as demonstrated by a complete inhibition of cell adhesion to ®bronectin by antibodies against the a5b1 integrin (data not shown and Guan et al., 1991) . As shown in Figure 2 (lane 1), overall tyrosine phosphorylation of proteins in suspended c-Cbl cells was negligible. Similar to the parental NIH3T3 cells (Burridge et al., 1992; Guan et al., 1991) , integrin-mediated cell attachment to ®bronectin resulted in elevated tyrosine phosphorylation of proteins of 115 ± 135 kDa, 70 ± 80 kDa and 55 ± 60 kDa in molecular weight (lane 2). By contrast, cells expressing mutant forms of Cbl displayed increased tyrosine phosphorylation of intracellular proteins when kept in suspension compared to cells expressing wildtype Cbl (lanes 1, 3, 5 and 7); this was most notable with protein(s) of 115 ± 135 kDa in molecular weight. Integrin-mediated cell attachment resulted in further increase in tyrosine phosphorylation of cellular proteins and, compared to cells expressing wild-type Cbl, proteins of 115 ± 135 kDa, 70 ± 80 kDa and 55 ± 60 kDa in molecular weight were hyperphosphorylated in cells expressing mutant forms of Cbl (lanes 2, 4, 6, 8) . Together, these results demonstrate that tyrosine phosphorylation events in cells expressing the wild-type form of Cbl, similar to untransfected ®broblasts, are largely dependent on integrin-mediated cell adhesion. In contrast, several polypeptides, most notably that (those) around 115 ± 135 kDa, are tyrosine phosphorylated in an adhesion-independent manner in cells expressing oncogenic forms of Cbl. Furthermore, several polypeptides demonstrated hyperphosphorylation in attached cells expressing oncogenic forms of Cbl. It therefore appears that expression of Cbl mutants induces deregulation of the endogenous tyrosine phosphorylation machinery, and as a result, requirement for integrin-mediated adhesion in some intracellular tyrosine phosphorylation events is bypassed in these cells.
In order to study the tyrosine phosphorylation status of the expressed Cbl proteins, samples from suspended and adherent NIH3T3 transfectants were immunoprecipitated with antibodies against Cbl, and analysed by immunoblotting with an anti-phosphotyrosine antibody ( Figure 3a ). When immunoprecipitated from suspended c-Cbl-expressing cells, Cbl exhibited a very low level of tyrosine phosphorylation ( Figure 3a , lane 1). An increase in tyrosine phosphorylation of cCbl was seen in cells plated on ®bronectin ( Figure 3a , lane 2). These results are indistinguishable from those we have reported for the endogenous Cbl in myeloid cells (Ojaniemi et al., 1997) and suggest that wild-type Cbl in NIH3T3 cells becomes phosphorylated in an integrin-regulated manner. In contrast, tyrosine phosphorylation of mutant forms of Cbl was readily detectable in cells kept in suspension; cell attachment to ®bronectin did not result in further increase in the tyrosine phosphorylation of the oncogenic Cblproteins (lanes 3 ± 8). Compared to tyrosine phosphorylation observed for wild-type Cbl in adherent cells, mutant forms of Cbl were hyperphosphorylated in suspended and attached cells. The experiments were carried out with and without prior serum starvation of the cells, and no dierences were found in the results between these two conditions (not shown). These results suggest that oncogenic forms of Cbl, unlike wild-type Cbl, become hyperphosphorylated on tyrosine in a manner independent of integrin-mediated cell adhesion.
By using speci®c antibodies against focal adhesion proteins p130
Cas and focal adhesion kinase FAK, we found that these proteins are among the 115 ± 135 kDa proteins that become tyrosine phosphorylated in an adhesion-dependent manner in c-Cbl-expressing cells and that are hyperphosphorylated in adherent, mutant Cbl-expressing cells; results for p130
Cas are shown in Figure 3b . Neither one of these proteins, however, demonstrated signi®cant adhesion-independent tyrosine phosphorylation in cells expressing oncogenic forms of Cbl. Similar results were obtained for paxillin, a 68 kDa focal adhesion protein (not shown). p130
Cas , FAK and paxillin are previously identi®ed components of the integrin signaling pathway (for a review, see Schwartz et al., 1995) . These results demonstrate that p130 Cas , FAK and paxillin are selectively hyperphosphorylated in attached cells expressing oncogenic forms of Cbl, but nevertheless their tyrosine phosphorylation is integrin-dependent in these cells. The identity of the protein(s) which, in addition to the oncogenic forms of Cbl, exhibit adhesion-independent tyrosine phosphorylation in these cells (see Figure 2) remains to be determined.
The tyrosine phosphorylated sites in c-Cbl have been found to function as binding sites for proteins containing SH2-domains, potentially connecting c-Cbl to a number of downstream signaling pathways (see Introduction). We have previously found that the endogenous c-Cbl protein interacts with a number of SH2-domain containing signaling molecules in an integrin ligand binding-dependent manner, and links Cas is hyperphosphorylated in NIH3T3 transfectants expressing oncogenic forms of Cbl in an adhesion-dependent manner. NIH3T3 transfectants expressing c-Cbl (lanes 1 and 2), 70Z/Cbl (lanes 3 and 4), Y368del (lanes 5 and 6) or Y371del (lanes 7 and 8) were either held in suspension (S; lanes 1, 3, 5 and 7) or plated on dishes coated with ®bronectin (Fn; lanes 2, 4, 6 and 8). Cas immunoprecipitates were separated by SDS ± PAGE and analysed by anti-phosphotyrosine immunoblot (upper panel). The immunoprecipitates were analysed by anti-Cas immunoblotting to con®rm equal loading (lower panel). Exposure time was 10 s for all the lanes in both panels c-Src and PI 3-kinase to the integrin signaling pathway in myeloid cells (Ojaniemi et al., 1997) . Binding experiments with various GST-SH2 fusion proteins demonstrated that wild-type Cbl expressed in 3T3 cells bound to SH2-domains in an adhesion-dependent manner; SH2-domain of Src, the p85 subunit of PI 3-kinase and the adapter protein Crk bound to wild-type Cbl in lysates of cells that had been plated on ®bronectin but not of cells that had been kept in suspension. In contrast, the mutant forms of Cbl readily interacted with the SH2-domains in both suspended and adherent cells (Figure 4 ). These results demonstrate that the oncogenic forms of Cbl are not only tyrosine phosphorylated in an adhesion-independent manner, but are capable of assembling and possibly activating intracellular signaling complexes in the absence of integrin-mediated cell adhesion. Indeed, we found that PI 3-kinase activity is associated with oncogenic forms of Cbl in both suspended and attached cells ( Figure 5 ). In contrast, PI 3-kinase activity was found to be associated with wild-type cCbl complexes in an adhesion-dependent manner. Total PI 3-kinase activity paralleled the Cbl-associated PI 3-kinase activity; PI 3-kinase activity was negligible in anti-phosphotyrosine immunoprecipitates in suspended cells expressing wild-type Cbl, whereas the activity was readily detectable in the immunoprecipitates prepared from attached wild-type Cbl-expressing cells and from suspended and attached mutant Cblexpressing cells (not shown). Similarly, tyrosine kinase activity was detected in Cbl immunoprecipitates from both suspended and adherent cells expressing oncogenic forms of Cbl (Figure 6 ). In contrast, tyrosine kinase activity associated with wild-type c-Cbl was markedly increased upon integrin-mediated cell adhesion to ®bronectin.
Growth characteristics of the Cbl-transfected cells
Our results suggest that the oncogenic forms of Cbl constitutively activate signaling pathways downstream of integrins and bypass the requirement for integrinmediated cell adhesion for these signaling events. To further analyse how the oncogenic forms of Cbl alter signaling pathways, proliferation of the various Cbltransfectants was studied. First, the ability of the various transfectants to grow in soft agar was tested. When put in semi-solid medium containing 10% serum, 3T3 cells transfected with oncogenic forms of Cbl rapidly formed large colonies (Table 1) . After 20 days, 24 ± 33% of the cells harboring oncogenic forms
Blot: α-CbI of Cbl formed colonies, as compared with 50.1% for control and wild-type Cbl-transfected 3T3 cells. These results con®rm the earlier ®ndings by others (Andoniou et al., 1994) and support the notion that cells expressing oncogenic forms of Cbl have a reduced requirement for integrin-induced signaling for proliferation. To determine if the transformed cells showed a reduced requirement for growth factors, the cells were tested for growth in soft agar containing 0.5% serum. Interestingly, transfectants expressing oncogenic forms of Cbl showed no detectable colony formation (50.1%) in semi-solid medium containing 0.5% serum (Table 1) , whereas other oncogenes including ras have been reported to induce colony formation in low serum (Oldham et al., 1996) . It therefore seems that unlike many other oncogenes, transforming mutants of Cbl do not abrogate the growth factor requirement for proliferation. The inability of oncogenic forms of Cbl to stimulate cell proliferation in a growth factor-independent manner was further demonstrated by other assays. Parental 3T3 cells and transfectant cell lines were plated on tissue culture dishes in medium with either 0.5% or 10% of serum. As shown in Figure 7a , no indication of serum-independent growth was detected, as all cell lines failed to proliferate in medium containing 0.5% serum. Both control and transfected cells died in serum-free medium (not shown). By contrast, ras-transformed cells have been reported to survive under serum-free conditions and show enhancement of proliferation in low serum (Mulcahy et al., 1985) . Parental 3T3 cells and transfected cell lines proliferated at a similar rate in the presence of 10% serum, with a doubling-time for proliferation being 22 h (Figure 7b ). Interestingly, parental NIH3T3 cells and c-Cbl-expressing cells appeared to reach saturation in their growth by day 8 under our assay conditions. In contrast, cells expressing oncogenic forms of Cbl continued to proliferate beyond this point, suggesting that oncogenic Cbl proteins may aect the contact inhibition of growth. As shown in Figure 7c , parental 3T3 cells, c-Cbl cells and transfectants expressing oncogenic forms of Cbl had similar proliferation rates at all serum concentrations tested (2 ± 10%) further demonstrating that all cell lines were similarly growth factor-dependent for growth. Similar results were obtained when the DNA synthesis rate of various transfectants was studied by measuring [ 3 Hlthymidine incorporation (not shown). Together, these results indicate that oncogenic forms of Cbl abrogate the adhesion-requirement, but not growth factor requirement for proliferation, and suggest that transformation by oncogenic forms of Cbl is mediated by activation of an integrin-dependent pathway.
Discussion
The ability of the naturally occurring and genetically engineered mutants of Cbl to transform NIH3T3 ®broblasts has provided an experimental system to (2, 4, 6, 8 or 10%) . Cell number was counted using hemocytometer on day 7 study the potential mechanisms of cellular transformation mediated by oncogenic forms of Cbl. Our results indicate that oncogenic forms of Cbl abrogate the adhesion requirement, but not the growth factor requirement for proliferation. The studies reported here therefore provide evidence for a novel mechanism of oncogenesis by mutant forms of Cbl, namely that of constitutive activation of an integrin-dependent signaling pathway. By implication, our studies identify a potential physiological role for the cellular form of Cbl in intracellular signaling of integrins.
Our studies demonstrate that the oncogenic forms of Cbl, unlike the wild-type form of Cbl, are tyrosine phosphorylated in an adhesion-independent manner. In addition, we found that oncogenic forms of Cbl in attached cells are hyperphosphorylated compared to the cellular form of Cbl. Previous studies have similarly concluded that oncogenic mutants of Cbl are hyperphosphorylated in cells growing as a monolayer (Andoniou et al., 1994; Bonita et al., 1997) ; the adhesionindependency and constitutive nature of the tyrosine phosphorylation has not been previously addressed. As a result of the constitutive tyrosine phosphorylation, the oncogenic forms of Cbl were able to bind to SH2-domains in both suspended and adherent cells. As there was a clear correlation between the constitutive tyrosine phosphorylation of Cbl and anchorage-independent growth, these data would suggest that tyrosine phosphorylation provides a biochemical mechanism for Cbl's transforming activity by promoting constitutive complex formation between Cbl and SH2 domaincontaining signaling proteins, such as Src and PI 3-kinase. As a result, these pathways would be constitutively active in integrin-independent manner, and by yet an unknown mechanism transform cells anchorage-independent. Indeed, we observed that PI 3-kinase is activated in an adhesion-independent manner in cells expressing oncogenic forms of Cbl. Interestingly, the transforming gene of the Cas-NS-1 retrovirus, v-Cbl, which represents a fusion of the ®rst 355 amino-terminal residues of the full-length Cbl protein to viral gag sequences, does not show detectable tyrosine phosphorylation (Blake et al., 1991; Bowtell and Langdon, 1995; Lupher et al., 1996) yet still induces anchorage-independent but growth factor-dependent growth (our unpublished results). These results suggest that either v-Cbl has a distinct mechanism for its oncogenic activity, or that constitutive tyrosine phosphorylation of mutant forms of Cbl used in this study is not the primary mechanism for anchorageindependency, but rather a re¯ection of dysregulated tyrosine kinase activity in the transformed cells.
In addition to the oncogenic Cbl proteins, several other polypeptides were hyperphosphorylated in cells expressing the mutant forms of Cbl. We found that the integrin signaling proteins p130 Cas , FAK and paxillin are among them; deregulated tyrosine phosphorylation of these proteins may contribute to the inadvertent activation of integrin signaling pathway. Recently, Bonita and coworkers found that the same transforming mutants of Cbl induced hyperphosphorylation of PDGF receptor and supported hyperproliferation of cells in a 7-day proliferation assay (Bonita et al., 1997) . Hyperresponsiveness to PDGF may explain the growth advantage the Cbl-transformed cells appeared to have at later time points in our proliferation experiments (see Figure 7b ). Since oncogenic Cbl proteins lack any enzymatic activity, it is not clear how these proteins induce the deregulation of the intracellular tyrosine phosphorylation machinery. Src-family kinases are among the candidate target tyrosine kinases, as well as the PDGF and EGF receptor tyrosine kinases, which have been shown to associate with Cbl (Bowtell and Langdon, 1995; Galisteo et al., 1995) . Cbl has also been shown to interact with tyrosine kinases ZAP-70/Syk through its recently identi®ed N-terminal PTB-domain (Lupher et al., 1996) . Our ®nding that oncogenic forms of Cbl are constitutively associated with tyrosine kinase activity and that they induce hyperphosphorylation of several intracellular proteins suggests a physiological role for cellular Cbl as a regulator of tyrosine kinases. To support this notion, c-Cbl has recently been implicated as a negative regulator of the Syk tyrosine kinase in FceRI signaling (Ota and Samelson, 1997) .
Although the exact mechanism remains to be determined, our ®ndings provide evidence that cellular transformation by oncogenic forms of Cbl occurs mainly by activation of an integrin-dependent, rather than growth factor-dependent pathway. We found no indication that oncogenic forms of Cbl would abrogate the growth factor-requirement for proliferation. This is in contrast to a behavior displayed by many other oncogenes, such as v-Ras and SV40 large T, which render cells both anchorage-and serum-independent. Previous results in experimental cell systems have indicated that constitutively activated form of FAK (Frisch et al., 1996) and oncogenic forms of Rho exchange factors also induce anchorage-independent but serum-dependent growth and make cells tumorigenic. Thus, our results add to the notion that anchorage independence and serum independence can be separated, which may be an important concept for understanding tumorigenesis. Recent ®ndings indicate that inadvertent activation of the integrin signaling pathway, without concomitant activation of the growth factor signaling, may truly contribute to human malignancies; Renshaw et al. (1995) found that the human leukemia oncogene bcrabl abrogates the anchorage requirement but not the growth factor requirement for proliferation. More recently, Lewis et al. (1996) reported that the cellular form of the abl kinase is a downstream component in integrin signaling, as it becomes activated upon integrin ligand binding. Interestingly, Cbl is the major tyrosine-phosphorylated protein in bcr-abl-transformed cells (Andoniou et al., 1994) , suggesting that Cbl may be the mediator for the transforming eects of bcr-abl. It should be noted, however, that our studies, as well as those by Renshaw et al. (1995) utilized NIH3T3 cells as the experimental model system; ®broblasts are not the targets of bcr-abl in vivo and neither do 3T3 cells express detectable levels of endogenous Cbl protein.
Although the ®nding that both bcr-abl and oncogenic forms of Cbl abrogate anchorage requirement for growth is consistent with many of the clinical manifestations of human chronic myelogenous leukemia; (for a review, see Verfaillie et al., 1997) , further studies in hematopoietic cells are required to fully explore the functional relevance of the ®ndings reported here and by Renshaw et al. (1995) .
By implication, our results suggest that a physiological role of cellular Cbl is to be a component of an integrin-dependent growth regulatory pathway. Assuming that the oncogenic forms of Cbl act in a dominantpositive manner, our ®ndings would suggest that the role of endogenous Cbl, through tyrosine phosphorylation or otherwise, is to support integrin-dependent cell proliferation. We cannot, however, rule out the possibility that the mutant forms of Cbl integrate into and activate the integrin pathway because of obtaining a new function as a result of the mutations. A possibility also exists that oncogenic mutants of Cbl function by a dominant-negative mechanism, inhibiting the function of the endogenous Cbl or, in 3T3 cells, a Cbl-like molecule. This explanation would lead to the opposite conclusion, namely that the function of cellular Cbl in the integrin pathway is to mediate growth inhibitory signals. Cbl may be a component of multiple signaling pathways; in addition to integrin-mediated cell attachment, tyrosine phosphorylation of cellular Cbl and binding to SH2-containing molecules has been reported to occur in response to a number of other stimuli. These include activation of the T-and B-cell antigen receptors (Cory et al., 1995; Donovan et al., 1994; Fukazawa et al., 1995; Kim et al., 1995; Panchamoorthy et al., 1996; Reedquist et al., 1994) , the GM-CSF, interleukin-3 and erythropoietin receptors Odai et al., 1995) , the Fcg receptor, the TPO/c-mpl receptor, the CD38 receptor and the CSF-1 receptor (Kontani et al., 1996; Sasaki et al., 1995; Tanaka et al., 1995; , and stimulation of receptors for EGF, PDGF, FGF and nerve growth factor (Bowtell and Langdon, 1995; Fukazawa et al., 1996; Galisteo et al., 1995; Meisner and Czech, 1995; Tanaka et al., 1995) . Although we did not ®nd evidence that constitutively tyrosine phosphorylated forms of Cbl would significantly aect growth factor signaling pathways, several ®ndings support the notion that Cbl would be an important component also in these pathways. Most notably, Cbl has been shown to be a regulator of the EGF receptor pathway; the C. elegans homolog of mammalian Cbl called SLI-1 is a negative regulator of the signaling downstream of the LET-23 receptor tyrosine kinase, a homolog of the mammalian EGF receptor (Jongeward et al., 1995) . More recently, Cbl has been implicated as a possible mediator for maintenance of T cell anergy (Boussiotis et al., 1997) . Further genetic and biochemical studies are required to fully discern the multiple important roles Cbl may have in intracellular signaling pathways.
Materials and methods

Reagents
Dulbecco's modi®ed Eagle's medium (DMEM) was supplied by Mediatech (Herndon, VA), fetal calf serum (FCS) was from Tissue Culture Biologicals (Tulare, CA) and Glutamine Pen-Strep from Irvine Scienti®c (Santa Ana, CA). Polyclonal rabbit anti-Cbl antibody was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Monoclonal anti-FAK antibody, monoclonal anti-paxillin antibody, monoclonal anti-Cas antibody, anti-phosphotyrosine antibody py20 and horseradish peroxidase (HRPO)-conjugated anti-phosphotyrosine antibody RC20 were from Transduction Laboratories (Lexington, KY). Human plasma ®bronectin was obtained from the Finnish Red Cross. All other reagents were acquired from Sigma.
Cell culture and cell adhesion NIH3T3 ®broblast cell lines expressing wild-type (c-Cbl) and transforming mutants of Cbl (70Z/Cbl, Y368del and Y371del) have been described previously (Andoniou et al., 1994) . Cells were grown in DMEM supplemented with 10% FCS, 50 units/ml penicillin and 50 mg/ml streptomycin. For the experiments, cells were grown into 90% con¯uency as monolayers, and detached with trypsin-EDTA treatment. Studies were also carried out with serum starving cells for 18 h in DMEM containing 0.3% FCS prior to detachment. Cells were then collected by centrifugation, washed twice with DMEM containing 0.5% BSA, and cell suspensions were incubated in DMEM with 0.5% BSA at 378C for 20 min on a rotator. Cells referred as adherent in Results were plated onto ®bronectin-coated (20 mg/ml) dishes and incubated at 378C for 45 min.
Preparations of Cell Lysates, Immunoprecipitations and Immunoblotting
Suspended and adherent cells were washed with ice-cold phosphate-buered saline (PBS) and lysed on ice for 15 min in modi®ed RIPA buer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 100 mM NaF, 0.5 mM Na 3 V0 4 , 1 mM EGTA, 0.1 U/ml aprotinin, 10 mg/ml leupeptin and 4 mg/ml pepstatin A). Lysates were cleared by centrifugation for 15 min and the supernatant was used in the experiments. Immunoprecipitations and immunoblot analysis were carried out as described earlier (Vuori and Ruoslahti, 1995) . Phosphotyrosine-containing proteins were visualized by incubating with HRPO-conjugated anti-phosphotyrosine antibody RC20 followed by enhanced chemiluminescence detection (Pierce). To detect Cbl, Cas, FAK or paxillin, the blots were probed with the corresponding antibodies, followed by HRPO-conjugated anti-mouse IgG or protein A. Immunoreactive bands were visualized by enhanced chemiluminescence.
SH2 binding assays
In vitro association experiments were done with glutathione-S-transferase (GST) fusion proteins containing the SH2-domains of PI 3-kinase (this construct contains the amino-terminal SH2-domain of PI 3-kinase, obtained from Dr Jerrold Olefsky, University of California at San Diego), Crk (obtained from Dr Michiyuki Matsuda, NIH, Japan) and Src (obtained from Dr Hisamaru Hirai, University of Tokyo, Tokyo, Japan). The fusion proteins were expressed in E. coli and puri®ed as described in . The fusion protein preparations were 495% pure as determined by SDS-polyacrylamide gel electrophoresis (PAGE) followed by Coomassie Blue staining. RIPA cell lysates containing equal amounts of protein were incubated with 5 mg of GST alone or of the GST ± SH2 fusion proteins, which had been immobilized on glutathione-Sepharose beads. After 2 h rotating at 48C, the beads were collected and washed twice with RIPA buer and twice with Tris-buered saline, and the bound proteins were released by boiling in sample buer followed by SDS ± PAGE and immunoblotting, as above.
In vitro kinase assays
For in vitro tyrosine kinase assays, Cbl was immunoprecipitated from suspended or adherent cells lysed in Nonidet P-40 buer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 100 mM NaF, 0.5 mM Na 3 V0 4 , 10 U/ml aprotinin, 10 mg/ml leupeptin and 4 mg/ ml pepstatin A) as described. The immunocomplexes were washed four times in NP-40 buer and once in kinase assay buer (50 mM HEPES, pH 7.5, 25 mM MgCl 2 , 4 mM MnCl 2 , 0.5 mM Na 3 V0 4 ) and suspended in 30 ml of kinase assay buer containing 4 mM ATP and 10 mCi of [g-32 P]ATP (6000 Ci/mmol; DuPont NEN). After incubation for 15 min in 308C, the phosphoproteins were separated by 4 ± 12% SDS ± PAGE and subjected to alkaline hydrolysis in 1 M KOH, after which tyrosinephosphorylated proteins were visualized by autoradiography. Relative amounts of Cbl were determined by immunoblot analysis of equal aliquots of the unlabeled immunoprecipitates.
For PI 3-kinase activity assays, cells were either kept in suspension, or plated on ®bronectin and lysed in Nonidet P-40/Triton X-100 buer (20 mM Tris, pH 7.5, 145 mM NaCl, 10% glycerol, 0.5% NP-40, 1% Triton X-100, 5 mM EDTA and phosphatase and protease inhibitors as above). Immunoprecipitations with anti-Cbl antibody, anti-phosphotyrosine antibody and a control nonrelated antibody were carried out as described. PI 3-kinase activity of the immunocomplexes was assayed according to Whitman et al. (1988) .
Cell growth assays
For anchorage-independent growth, 1000 cells were suspended in 1.5 ml of 0.3% of melted soft agar in DMEM containing either 0.5% or 10% FCS and seeded to 35 mm wells coated with 1.5 ml of 0.5% agarose in the respective media. Colonies of eight cells or more were counted after 20 days using microscope. For proliferation assays, cells were plated on 35 mm wells at 10 000 cells/ well in medium containing 10% FCS. After 12 h media were changed to contain varying concentrations of serum as indicated in ®gure legends and the cells were re-fed every 3 days. Cell number was counted using hemocytometer at time points indicated. For thymidine incorporation assays, cells were plated on 96-well dishes at 10 000 cells/well in DMEM containing 10% FCS. After 12 h the medium was switched to contain 0.5% FCS and cells were starved for 48 h. Fresh medium containing 0.5% FCS or 10% FCS was changed to the cells 15 h before a 3-h pulse-labeling of the cells with [
3 H]thymidine (1 mCi/well). The amount of incorporated thymidine was measured by automatic scintillation counter. All experiments were carried out three independent times in triplicates.
